Trevena, Inc. (TRVN) Initiates Phase 2 Study Of TRV130 In Acute Postoperative Pain
5/1/2014 2:35:02 PM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the initiation of a Phase 2a/b clinical trial with TRV130, a small molecule G protein biased ligand at the mu opioid receptor, which Trevena is developing as a first-line intravenous treatment for patients experiencing moderate to severe acute pain where intravenous administration is preferred.
Help employers find you! Check out all the jobs and post your resume.
comments powered by